These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28801576)

  • 1. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
    Chen R; Lai LA; Sullivan Y; Wong M; Wang L; Riddell J; Jung L; Pillarisetty VG; Brentnall TA; Pan S
    Sci Rep; 2017 Aug; 7(1):7950. PubMed ID: 28801576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Qiu J; You L; Zheng L; Zhang T; Zhao Y
    J Exp Clin Cancer Res; 2018 Nov; 37(1):274. PubMed ID: 30419950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
    Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
    Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
    Park JM; Peng JM; Shen YS; Lin CY; Hsu TW; Su YH; Chen HA; Saengboonmee C; Chang JS; Chiu CF; Shan YS
    Mol Metab; 2022 Nov; 65():101576. PubMed ID: 35995401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
    Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
    Zou J; Su H; Zou C; Liang X; Fei Z
    J Biochem Mol Toxicol; 2020 Jun; 34(6):e22480. PubMed ID: 32104955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells.
    Fujimura Y; Ikenaga N; Ohuchida K; Setoyama D; Irie M; Miura D; Wariishi H; Murata M; Mizumoto K; Hashizume M; Tanaka M
    Pancreas; 2014 Mar; 43(2):311-8. PubMed ID: 24518513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.
    Sharma NS; Gupta VK; Garrido VT; Hadad R; Durden BC; Kesh K; Giri B; Ferrantella A; Dudeja V; Saluja A; Banerjee S
    J Clin Invest; 2020 Jan; 130(1):451-465. PubMed ID: 31613799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
    Li J; Liang X; Yang X
    Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
    Ishida M; Sunamura M; Furukawa T; Akada M; Fujimura H; Shibuya E; Egawa S; Unno M; Horii A
    World J Gastroenterol; 2007 Sep; 13(34):4593-7. PubMed ID: 17729412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
    Kim YJ; Hong YB; Cho CH; Seong YS; Bae I
    Pancreas; 2012 Jul; 41(5):804-5. PubMed ID: 22695089
    [No Abstract]   [Full Text] [Related]  

  • 12. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
    Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
    Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
    Hashim YM; Vangveravong S; Sankpal NV; Binder PS; Liu J; Goedegebuure SP; Mach RH; Spitzer D; Hawkins WG
    J Exp Clin Cancer Res; 2017 Jan; 36(1):14. PubMed ID: 28095907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
    Mu GG; Zhang LL; Li HY; Liao Y; Yu HG
    Dig Dis Sci; 2015 Apr; 60(4):1067-80. PubMed ID: 25344906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
    Ma T; Chen W; Zhi X; Liu H; Zhou Y; Chen BW; Hu L; Shen J; Zheng X; Zhang S; Zhang B; Li H; Liang T
    Cancer Lett; 2018 Nov; 436():129-138. PubMed ID: 30118840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.
    Cheng X; Holenya P; Can S; Alborzinia H; Rubbiani R; Ott I; Wölfl S
    Mol Cancer; 2014 Sep; 13():221. PubMed ID: 25253202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
    Peng T; Dou QP
    J Cell Biochem; 2017 Sep; 118(9):2722-2730. PubMed ID: 28165150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.